MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Cancer risks of blood pressure medications

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Cancer risks of blood pressure medications




University Hospitals Case Medical Center heart specialists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

This class of drugs is used by millions of patients not only for hypertension but also for heart failure, cardiovascular risk reduction and diabetic kidney disease.

University Hospitals Harrington-McLaughlin Heart & Vascular Institute's Drs. Ilke Sipahi, Daniel I. Simon and James C. Fang recently completed a meta-analysis of over 60,000 patients randomly assigned to take either an ARB or a control medication. Their findings are published online today at The Lancet Oncology
The scientists observed that patients randomized to ARBs has "significantly increased risk of new cancer" in comparison to control patients.



Cancer risks of blood pressure medications

"We have found the risk of new cancers was increased with these medications by 8-11 percent," said Dr. Ilke Sipahi, associate director of heart failure and transplantation and assistant professor at Case Western Reserve University School of Medicine. "Most importantly, risk of lung cancer was increased by 25 percent".

However, the research did not establish any link between ARBs and other types of cancer such breast cancer.

"This is the first time an association between ARBs and cancer development is suggested," Dr. Sipahi continued. "While our findings are robust, they need to be replicated in other studies before they can be considered as definitive".

Before this study, there were no major safety concerns with ARBs except for their use in pregnancy and in patients with chronic kidney or blockages of kidney arteries. Interestingly, prior animal studies with ARBs have been negative for cancer development.

"In medicine, physicians must balance the benefits and risks of all drug and device therapies," said Dr. Daniel Simon, director of the Harrington-McLaughlin Heart & Vascular Institute at University Hospitals Case Medical Center and professor at Case Western Reserve University School of Medicine. "We recommend that patients discuss the findings of this study with their physicians since ARBs are effective agents in the therapy of hypertension and heart failure. Meta-analyses are a powerful tool to look at low frequency safety signals, but require confirmation with other approaches, such as large national health and managed care registries".


Posted by: Janet    Source




Did you know?
University Hospitals Case Medical Center heart specialists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs). This class of drugs is used by millions of patients not only for hypertension but also for heart failure, cardiovascular risk reduction and diabetic kidney disease.

Medicineworld.org: Cancer risks of blood pressure medications

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.